Nicholas GalakatosGlobal Head of Life Sciences at Blackstone
Nicholas Galakatos is the Head of the Blackstone Life Sciences business, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception. Dr.Galakatos has over 30 years of industry and investment experience and has led investments in biotechnology, pharmaceutical company partnerships, and diagnostics, from startups to commercial-stage. Prior to Clarus, Dr. Galakatos was a General Partner at MPM Capital,. From 1997 to 2000 he was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the Management Team. He is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO Dr. Galakatos is the Chairman of Anthos Therapeutics and Praxis Precision Medicine, and a member of the Board of Directors of Entasis Therapeutics (NASDAQ: ETTX) and Talaris, Inc.